|
LNPEP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.94450000054769E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.32819999999023E-05 |
| Normal-vs-Stage2 |
1.437730E-03 |
| Normal-vs-Stage3 |
6.79270000025767E-07 |
| Normal-vs-Stage4 |
2.31729999999875E-06 |
| Stage1-vs-Stage2 |
8.023800E-01 |
| Stage1-vs-Stage3 |
2.498800E-01 |
| Stage1-vs-Stage4 |
1.255980E-01 |
| Stage2-vs-Stage3 |
6.214800E-01 |
| Stage2-vs-Stage4 |
4.405400E-01 |
| Stage3-vs-Stage4 |
6.842000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.06250000001074E-06 |
| Normal-vs-AfricanAmerican |
3.504500E-02 |
| Normal-vs-Asian |
1.59482999999572E-05 |
| Caucasian-vs-AfricanAmerican |
4.244000E-01 |
| Caucasian-vs-Asian |
2.203200E-01 |
| AfricanAmerican-vs-Asian |
1.196440E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.16219999957146E-07 |
| Normal-vs-Female |
3.66000000000533E-05 |
| Male-vs-Female |
1.036070E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.024400E-04 |
| Normal-vs-Age(41-60Yrs) |
7.68819999996673E-07 |
| Normal-vs-Age(61-80Yrs) |
1.67341999999238E-05 |
| Normal-vs-Age(81-100Yrs) |
1.197580E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.872610E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.326000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.848600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.080000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.303800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.701000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.608300E-02 |
| Classical-VS-Follicular |
1.173770E-02 |
| Classical-VS-Other |
7.477700E-03 |
| Classical-VS-Normal |
1.026350E-04 |
| Tall-VS-Follicular |
9.260200E-01 |
| Tall-VS-Other |
2.317400E-01 |
| Tall-VS-Normal |
4.01159999999789E-05 |
| Follicular-VS-Other |
2.743800E-01 |
| Follicular-VS-Normal |
1.66740000029364E-07 |
| Other-VS-Normal |
3.69850000000449E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.41519999958307E-07 |
| Normal-vs-N1 |
2.07389999999918E-05 |
| N0-vs-N1 |
5.782800E-01 |
|
|
